Novel approaches in treating gastrointestinal neuroendocrine tumors
Nitya Raj, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses emerging treatment options for patients with neuroendocrine tumors (NETs) located in the gastrointestinal tract. Whilst there are a number of therapies such as radiopharmaceutical treatments currently available, clinicians need to elucidate which therapies are suited for a particular patient. Prospective data from the Phase II ECOG-ACRIN E2211 trial (NCT01824875) have additionally assessed the role of capecitabine and temozolomide in patients with pancreatic NETs. This interview took place virtually at the 2022 Great Debates & Updates in Gastrointestinal Malignancies Congress.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
No comments found